RAPP Rapport Therapeutics Inc

$RAPP ➡️ $MCRB $XBI $IBB TWO DIP BUYS. TWO SOLID TRADES. PROFITS ROTATING! 💰📈 Caught two nice dips on $RAPP this morning and came away with some profits.💵 Now what am I doing with those gains? FUNNELING PROFITS INTO $MCRB 🚀 👀 SER-428 DATA PRESENTATION THIS THURSDAY, OCTOBER 22! Two days away! Take profits where opportunity presents itself. Rotate capital into where YOU believe the risk/reward is most compelling. For me, $MCRB has the best R:R in all of smid caps biotech!🔥 ~$25M market cap. Trading below cash. No debt. Cash runway through March 2027. The market has absolutely demolished this stock, but I continue to believe the pipeline is being valued at a fraction of its potential. Could Thursday's SER-428 presentation bring more attention to the story? Could we see additional PRs ahead of the Q3 earnings and business update in early November?👀 RAPP paid me this morning. Now I'm putting those profits to work where I see the bigger opportunity LET'S GO, $MCRB !💰

$RAPP Not saying stocks should always rise coz of good news - but this big of drops the day after pretty decent news is plain weird 😬

Wells Fargo $RAPP (Overweight-$51) $JNJ PRAX $ABBV OVID XENE ESAIY BMY ANRO NRXP UCBJY GSK CPRX Well Fargo said—RAP-219 generated a +VE efficacy signal in bipolar mania—however thinks stock upside will be capped given the imbalance in agitation TEAEs and the high discontinuation rate—thinks investors viewed this study as risky from both an efficacy perspective given is an untested MoA in Bipolar, and a safety perspective given the potential for aggression to occur based on the underlying disease.

$RAPP not financial advice: I've never liked RAPP. come to SLS, IBRX & PDSB to recover your losses. GL.

$RAPP I am done with biotech stocks…. Why the offerring ?? Why so much ?? Why now and not after quarter results or new FOS data YE ? Rapport currently intends to use the net proceeds to fund its ongoing and planned clinical trials advancing RAP-219, for other research and development, and for working capital and general corporate purposes. Rapport also may use a portion of the remaining net proceeds to in-license, acquire or invest in complementary businesses, technologies, products or assets…. Press Release Aug 5th : The Company ended the second quarter of 2026 with $436.1 million in cash, cash equivalents and short-term investments, excluding restricted cash, compared to $476.8 million as of March 31, 2026. Cash Runway: The Company expects that cash, cash equivalents, and short-term investments as of June 30, 2026, will enable it to fund its operating expenses and capital expenditure requirements into the second half of 2029.

$RAPP with 478mil in cash, almost $10/sh. Why is it manipulated so you give up your shares. Time to accumulate.

$RAPP No, it's actually the way biotech stocks are manipulated. Seen it 1,000 times. Good news comes out, they short the piss out of these stocks and load up.

$RAPP Who owns $RAPP? A look at Rapport Therapeutics’ major institutional investors: • Third Rock Ventures: 7.25M shares — 15.11% • Fidelity (FMR): 7.17M shares — 14.95% • ARCH Venture Partners: 3.73M shares — 7.77% • Capital Research & Management: 3.47M shares — 7.24% • BlackRock: 2.70M shares — 5.63% • Cormorant Asset Management: 2.66M shares — 5.54% • Sofinnova Investments: 1.90M shares — 3.97% • Johnson & Johnson Innovation (JJDC): 1.78M shares — 3.72%

$RAPP 66% short today. The rolling five day looks to be about 65% as well. That's why the stock came down. The drug hit on all endpoints. Pretty good considering its main use is for epilepsy and treating bi polarism would be secondary.

$RAPP BTIG raised theirs today: $75 → $89, Buy. Consensus target is $65 (MarketBeat). Others: UBS $71, HC Wainwright $66, Guggenheim $65, Leerink $52, Wolfe $50 (initiated last week). Outlook: Jefferies sees billions in peak sales. They value the epilepsy franchise alone at $2.2B against a ~$1.4B market cap, with bipolar mania as $1B+ of unpriced optionality. Cash $436M, runway into late 2029.

253 patients and $RAPP hit both ends of it Phase 2 RAP 219 in bipolar mania YMRS down 15.4 points on drug vs 12.3 on placebo at week 3, placebo adjusted win 3.1, p equals 0.045 no severe or serious events, every event mild or moderate up over 20 percent premarket off a $28.60 close and people are still arguing about the 3.1 like the secondary didn't hit too imo

$RAPP Mentioned this yesterday that it was going back to $26 where directors were buying. Been a good trade from $22 in a crappy market

$RAPP what happened today is all the shorts had to cover and then the price went up a lot and then went down a little bit after that I could tell because they put the Call ratio went from four to under one, so I don’t know if we’re gonna see an increase or decrease tomorrow, this could’ve been a one off. What do people think? 

$RAPP Offering today - Rapport Therapeutics(RAPP) said Wednesday it priced separate offerings of $175 million of common stock at $21 per share, along with pre-funded warrants, and $150 million of 2.25% convertible senior notes due 2032.

$RAPP: Rapport Therapeutics priced a $175 million stock offering at $21 per share, $150 million convertible notes, and a $30 million private placement.

$RAPP Is Rapport's $350M stock-and-convertible raise worth the dilution for holders? 🏢 Rapport Therapeutics, a neuroscience biotech whose Oct 20 8-K said its Phase 2 bipolar mania trial met its main goal, launched $200.0M of stock and $150.0M of convertible notes due 2032 on Oct 27, plus a private placement 📈 In return, Rapport would get $350M gross before fees if both underwritten sales close, plus up to $52.5M more if underwriters use their options and an unsized private placement; it said its $436.1M at June 30 alone was expected to fund operations into the second half of 2029, with a PGTCS Phase 3 trial expected to begin in the first half of 2027, two bipolar Phase 3 trials in the second half of 2027, and proceeds aimed mainly at RAP-219 trials 📅 Next: Pricing of the stock and notes; open-label focal seizure data are expected in the fourth quarter of 2026 Source: SEC 424B5s + GlobeNewswire release, Oct 27

$RAPP they def have good news to fund. No way the directors would have bought knowing a 20 percent drop. They need to fund. Clean balance sheet and long run way.

$RAPP Why would directors be buying at $27 knowing an offering was in the works. Something more might be going on here.

$RAPP weirdest price action I’ve seen in bio for a while, all the big boys raising price targets, the boiler indication was always a bonus, this company is trading at lower than when initial P2 epilepsy data was released and that is their 1 show pony to a buyout from the big boys, not sure why the hate here. Anybody?

$RAPP SOLD IT AS SAME AMO AS YESTERDAY INTO SPCX GOOD LUCK ALL 🤷‍♂️🤷‍♂️ WORRIED ABOUT THE EFFICACY ITS SAYS MODEST THATS WHY IT FELL BIG STRANGE THOUGH